---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-23-000004"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:07:26.060253+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q4 net loss $30.5M; NDA for sotagliflozin on track for May PDUFA

## Summary
- Net loss $30.5M ($0.16 per share) vs $25.6M ($0.17) in Q4 2021; full-year loss $101.9M ($0.62).
- R&D expenses $14.0M (down from $16.5M); SG&A $16.3M (up from $8.8M) due to launch prep.
- Cash and investments $138.4M as of Dec 31, 2022, up from $86.7M year-end 2021.
- Sotagliflozin NDA for heart failure on track for May 2023 PDUFA date after FDA late-cycle review.
- LX9211 showed consistent results in diabetic neuropathic pain; PHN study missed primary endpoint (p=0.12) but showed evidence of effect.

## SEC filing metadata
- accession: 0001062822-23-000004
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/lxrx-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-23-000004
- JSON: https://secwatch.observer/filing/0001062822-23-000004.json
- Plain text: https://secwatch.observer/filing/0001062822-23-000004.txt

## Key facts
- Earnings Releases
  LEXICON PHARMACEUTICALS, INC. reported the three months ended December 31, 2022 results: net income Net loss of $30.5 million, or $0.16 per share, EPS $0.16 per share.
  - Period: the three months ended December 31, 2022
  - Net income: Net loss of $30.5 million, or $0.16 per share
  - EPS: $0.16 per share
  - Result: reported results
  source text: Net loss for the fourth quarter of 2022 was $30.5 million, or $0.16 per share, as compared to a net loss of $25.6 million, or $0.17 per share, in the corresponding period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm
- Earnings Releases
  LEXICON PHARMACEUTICALS, INC. reported the full-year ended December 31, 2022 results: net income Net loss of $101.9 million, or $0.62 per share, EPS $0.62 per share.
  - Period: the full-year ended December 31, 2022
  - Net income: Net loss of $101.9 million, or $0.62 per share
  - EPS: $0.62 per share
  - Result: reported results
  source text: Net loss for the full-year 2022 was $101.9 million, or $0.62 per share, as compared to a net loss of $87.8 million, or $0.60 per share in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.